Aragon obtains $42M in funding for cancer drug development

03/7/2012 | Genetic Engineering & Biotechnology News

Aragon Pharmaceuticals secured $42 million in a Series C funding round headed by new investor Topspin Fund. The money will be used to advance the development of Aragon's early clinical and preclinical androgen receptor- and estrogen receptor-targeting drugs for certain prostate and breast cancers.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR